These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20591025)

  • 21. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Follow-up of the kidney donor].
    Bonfante L; Gemelli A; D'Angelo A
    G Ital Nefrol; 2009; 26(4):460-7. PubMed ID: 19644835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
    Yoshida D; Higashiura K; Shimamoto K
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():533-7. PubMed ID: 15779436
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Sri Lankan community.
    Illangasekera U; Nugegoda DB; Perera LS
    Ceylon Med J; 1993 Sep; 38(3):123-6. PubMed ID: 7828231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underestimating the risk in living kidney donation.
    Glannon W
    J Med Ethics; 2008 Mar; 34(3):127-8. PubMed ID: 18316448
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.
    Deedwania PC; Fonseca VA
    Am J Med; 2005 Sep; 118(9):939-47. PubMed ID: 16164876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective observational study of changes in renal function and cardiovascular risk following living kidney donation.
    Prasad GV; Lipszyc D; Huang M; Nash MM; Rapi L
    Transplantation; 2008 Nov; 86(9):1315-8. PubMed ID: 19005415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Impaired glucose tolerance (IGT): current understanding and future research directions].
    Terauchi Y; Kadowaki T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():21-6. PubMed ID: 15779340
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk factors for the development of new-onset diabetes mellitus in a living related renal transplant program.
    Bora GS; Guleria S; Reddy VS; Tandon N; Gupta N; Gupta S; Bhowmik D
    Transplant Proc; 2010 Dec; 42(10):4072-3. PubMed ID: 21168630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of the living renal donor. Analysis of extra-renal pathology as a limitation for donation].
    Díaz JM; Guirado L; Facundo C; García-Maset R; Solà R
    Nefrologia; 2005; 25 Suppl 2():51-6. PubMed ID: 16050403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose and cardiovascular risk.
    Fuchs M; Hoekstra JB; Mudde AH
    Neth J Med; 2002 Jun; 60(5):192-9. PubMed ID: 12365474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing incidence of abnormal glucose tolerance in women with prior abnormal glucose tolerance during pregnancy: DIAGEST 2 study.
    Vambergue A; Dognin C; Boulogne A; Réjou MC; Biausque S; Fontaine P
    Diabet Med; 2008 Jan; 25(1):58-64. PubMed ID: 18028442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CARI guidelines. Surgical techniques in living donor nephrectomy.
    Gibbons N; Nicol D;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S88-95. PubMed ID: 20591051
    [No Abstract]   [Full Text] [Related]  

  • 34. [Borderline type, impaired glucose tolerance (IGT), and impaired fasting glucose (IFG): their concepts, classification and significance].
    Kuzuya T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():15-20. PubMed ID: 15779339
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Palestinian population.
    Husseini A; Abdul-Rahim H; Awartani F; Jervell J; Bjertness E
    East Mediterr Health J; 2000; 6(5-6):1039-45. PubMed ID: 12197326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Living kidney donors: the need to minimise long term risk.
    Trevitt R
    J Ren Care; 2011 Sep; 37(3):134-47. PubMed ID: 21810195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Living donor kidney donation improves transplantation outcome. How risky is it for the donor?].
    Koczorek M
    MMW Fortschr Med; 2002 Aug; 144(33-34):14. PubMed ID: 12380137
    [No Abstract]   [Full Text] [Related]  

  • 38. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test.
    Caillard S; Eprinchard L; Perrin P; Braun L; Heibel F; Moreau F; Kessler L; Moulin B
    Transplantation; 2011 Apr; 91(7):757-64. PubMed ID: 21336240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential risks of living kidney donation--a review.
    Gai M; Giunti S; Lanfranco G; Segoloni GP
    Nephrol Dial Transplant; 2007 Nov; 22(11):3122-7. PubMed ID: 17640938
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.
    Bowman L; Armitage J
    Semin Vasc Med; 2002 Nov; 2(4):383-9. PubMed ID: 16222628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.